[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fPlqh7M53qanDq8v7_pREoIxFohwNmV5_BVYsZsHgWho":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"University of Ottawa",[4],115,false,26,4,12678,0,100,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Heat Stress",19,{"name":18,"count":19},"Aging",12,{"name":21,"count":22},"Physiological Stress",9,{"name":24,"count":25},"Hyperthermia",7,{"name":27,"count":28},"Cancer",5,{"name":30,"count":28},"Thermoregulation",{"name":32,"count":28},"Exercise",{"name":34,"count":9},"Multiple Sclerosis",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,72,100,118,136,163,181,208,233,260,278,303,328,354,372,390,412,439,457,475,493,518,544,569],{"intervention":45,"totalTrials":46,"cells":47},"Escitalopram",1,{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":70},{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[],{"trials":57,"activeCount":11},[58],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NCT00708240","Treatment Youth With Obsessive-Compulsive Disorder","UNKNOWN",[41],"2010-08","2010-12","2007-01",40,[68],"Obsessive Compulsive Disorder",[45],{"trials":71,"activeCount":11},[],{"intervention":73,"totalTrials":46,"cells":74},"Levomilnacipran",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":98},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":86,"briefTitle":87,"status":61,"phases":88,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":95},"NCT03249311","Levomilnacipran in Healthy Males",[41],"2019-12-31","2022-05-01","2018-03-02",36,[94],"None (i.e. Healthy Volunteers)",[73,96,97],"Duloxetine","Placebos",{"trials":99,"activeCount":11},[],{"intervention":96,"totalTrials":46,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":116},{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[],{"trials":111,"activeCount":11},[112],{"nctId":86,"briefTitle":87,"status":61,"phases":113,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":114,"interventions":115},[41],[94],[73,96,97],{"trials":117,"activeCount":11},[],{"intervention":97,"totalTrials":46,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":134},{"trials":121,"activeCount":11},[],{"trials":123,"activeCount":11},[],{"trials":125,"activeCount":11},[],{"trials":127,"activeCount":11},[],{"trials":129,"activeCount":11},[130],{"nctId":86,"briefTitle":87,"status":61,"phases":131,"primaryCompletion":89,"completion":90,"start":91,"enrollment":92,"conditions":132,"interventions":133},[41],[94],[73,96,97],{"trials":135,"activeCount":11},[],{"intervention":137,"totalTrials":46,"cells":138},"Ketamine",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":159,"NA":161},{"trials":140,"activeCount":11},[],{"trials":142,"activeCount":11},[],{"trials":144,"activeCount":11},[],{"trials":146,"activeCount":11},[147],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT01945047","Action of Ketamine in Treatment-Resistant Depression","COMPLETED",[39,40],"2017-12","2013-05",46,[156],"Treatment-resistant Depression",[137,158],"Midazolam",{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[],{"intervention":158,"totalTrials":46,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":177,"NA":179},{"trials":166,"activeCount":11},[],{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[173],{"nctId":148,"briefTitle":149,"status":150,"phases":174,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":175,"interventions":176},[39,40],[156],[137,158],{"trials":178,"activeCount":11},[],{"trials":180,"activeCount":11},[],{"intervention":182,"totalTrials":46,"cells":183},"Intravenous Ketamine",{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":204,"NA":206},{"trials":185,"activeCount":11},[],{"trials":187,"activeCount":11},[],{"trials":189,"activeCount":11},[],{"trials":191,"activeCount":11},[192],{"nctId":193,"briefTitle":194,"status":195,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":203},"NCT03674671","Ketamine Versus Electroconvulsive Therapy in Depression","SUSPENDED",[40],"2025-12","2018-10-29",240,[201,202],"Depressive Disorder, Major","Bipolar Depression",[182],{"trials":205,"activeCount":11},[],{"trials":207,"activeCount":11},[],{"intervention":209,"totalTrials":46,"cells":210},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":229,"NA":231},{"trials":212,"activeCount":11},[],{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[],{"trials":218,"activeCount":11},[219],{"nctId":220,"briefTitle":221,"status":61,"phases":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT00394498","Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair",[39,40],"2006-10","2005-09",86,[227],"Myocardial Infarction",[209],{"trials":230,"activeCount":11},[],{"trials":232,"activeCount":11},[],{"intervention":234,"totalTrials":46,"cells":235},"Ketamine Hydrochloride",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":256,"NA":258},{"trials":237,"activeCount":11},[],{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[],{"trials":243,"activeCount":11},[244],{"nctId":245,"briefTitle":246,"status":61,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT05468840","Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation",[40],"2023-12","2024-07","2023-06",20,[253],"Suicidal Ideation",[234,255],"Normal saline",{"trials":257,"activeCount":11},[],{"trials":259,"activeCount":11},[],{"intervention":255,"totalTrials":46,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":274,"NA":276},{"trials":263,"activeCount":11},[],{"trials":265,"activeCount":11},[],{"trials":267,"activeCount":11},[],{"trials":269,"activeCount":11},[270],{"nctId":245,"briefTitle":246,"status":61,"phases":271,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":272,"interventions":273},[40],[253],[234,255],{"trials":275,"activeCount":11},[],{"trials":277,"activeCount":11},[],{"intervention":279,"totalTrials":46,"cells":280},"Dextromethorphan",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":282,"activeCount":11},[],{"trials":284,"activeCount":11},[],{"trials":286,"activeCount":11},[287],{"nctId":288,"briefTitle":289,"status":61,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":19,"conditions":294,"interventions":296},"NCT02426983","Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination",[38,39],"2015-09","2016-04","2015-04",[295],"Schizophrenia",[279],{"trials":298,"activeCount":11},[],{"trials":300,"activeCount":11},[],{"trials":302,"activeCount":11},[],{"intervention":304,"totalTrials":46,"cells":305},"Cipralex®",{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":307,"activeCount":11},[],{"trials":309,"activeCount":11},[310],{"nctId":311,"briefTitle":312,"status":61,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":319},"NCT01293838","Cipralex® for Anxiety Disorders in Adolescents",[38],"2012-01","2008-03",30,[318],"Anxiety Disorder",[304],{"trials":321,"activeCount":11},[],{"trials":323,"activeCount":11},[],{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[],{"intervention":329,"totalTrials":46,"cells":330},"Trazodone",{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":332,"activeCount":11},[],{"trials":334,"activeCount":11},[335],{"nctId":336,"briefTitle":337,"status":61,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":316,"conditions":341,"interventions":343},"NCT01400165","Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations",[38],"2011-12","2011-07",[342],"Healthy",[329,344,345],"Quetiapine","Pindolol",{"trials":347,"activeCount":11},[],{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[],{"intervention":344,"totalTrials":46,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":370},{"trials":357,"activeCount":11},[],{"trials":359,"activeCount":11},[360],{"nctId":336,"briefTitle":337,"status":61,"phases":361,"primaryCompletion":339,"completion":339,"start":340,"enrollment":316,"conditions":362,"interventions":363},[38],[342],[329,344,345],{"trials":365,"activeCount":11},[],{"trials":367,"activeCount":11},[],{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[],{"intervention":345,"totalTrials":46,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[378],{"nctId":336,"briefTitle":337,"status":61,"phases":379,"primaryCompletion":339,"completion":339,"start":340,"enrollment":316,"conditions":380,"interventions":381},[38],[342],[329,344,345],{"trials":383,"activeCount":11},[],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[],{"trials":389,"activeCount":11},[],{"intervention":391,"totalTrials":46,"cells":392},"Desvenlafaxine succinate",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":410},{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[397],{"nctId":398,"briefTitle":399,"status":61,"phases":400,"primaryCompletion":339,"completion":339,"start":401,"enrollment":251,"conditions":402,"interventions":403},"NCT01101152","Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers",[38],"2010-04",[342],[391],{"trials":405,"activeCount":11},[],{"trials":407,"activeCount":11},[],{"trials":409,"activeCount":11},[],{"trials":411,"activeCount":11},[],{"intervention":413,"totalTrials":46,"cells":414},"Venlafaxine",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":416,"activeCount":11},[],{"trials":418,"activeCount":11},[419],{"nctId":420,"briefTitle":421,"status":150,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":427},"NCT00676039","Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations",[38],"2008-07","2007-11",18,[342],[413,428,429,430],"Gen-Citalopram","Effexor XR","Celexa",{"trials":432,"activeCount":11},[],{"trials":434,"activeCount":11},[],{"trials":436,"activeCount":11},[],{"trials":438,"activeCount":11},[],{"intervention":428,"totalTrials":46,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":11},[],{"trials":444,"activeCount":11},[445],{"nctId":420,"briefTitle":421,"status":150,"phases":446,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":447,"interventions":448},[38],[342],[413,428,429,430],{"trials":450,"activeCount":11},[],{"trials":452,"activeCount":11},[],{"trials":454,"activeCount":11},[],{"trials":456,"activeCount":11},[],{"intervention":429,"totalTrials":46,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":460,"activeCount":11},[],{"trials":462,"activeCount":11},[463],{"nctId":420,"briefTitle":421,"status":150,"phases":464,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":465,"interventions":466},[38],[342],[413,428,429,430],{"trials":468,"activeCount":11},[],{"trials":470,"activeCount":11},[],{"trials":472,"activeCount":11},[],{"trials":474,"activeCount":11},[],{"intervention":430,"totalTrials":46,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":478,"activeCount":11},[],{"trials":480,"activeCount":11},[481],{"nctId":420,"briefTitle":421,"status":150,"phases":482,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":483,"interventions":484},[38],[342],[413,428,429,430],{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[],{"trials":490,"activeCount":11},[],{"trials":492,"activeCount":11},[],{"intervention":494,"totalTrials":46,"cells":495},"Lidocaine Intravenous",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":497,"activeCount":11},[],{"trials":499,"activeCount":11},[],{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[508],{"nctId":509,"briefTitle":510,"status":150,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":517},"NCT00382499","Intraoperative Lidocaine Infusion for Analgesia (ILIA)",[42],"2008-12","2006-11",93,[516],"Elective Total or Subtotal Abdominal Hysterectomy",[494],{"intervention":519,"totalTrials":46,"cells":520},"BEACON + Problem Solving Therapy",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":522,"activeCount":11},[],{"trials":524,"activeCount":11},[],{"trials":526,"activeCount":11},[],{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"trials":532,"activeCount":11},[533],{"nctId":534,"briefTitle":535,"status":61,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":12,"conditions":540,"interventions":543},"NCT03473535","BEACON Suicide Prevention in Men Study",[42],"2023-03-31","2024-09-23","2020-03-31",[541,542],"Intentional Self-Harm","Suicide",[519],{"intervention":545,"totalTrials":46,"cells":546},"Adrenocorticotrophic hormone",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":548,"activeCount":11},[],{"trials":550,"activeCount":11},[],{"trials":552,"activeCount":11},[],{"trials":554,"activeCount":11},[],{"trials":556,"activeCount":11},[],{"trials":558,"activeCount":11},[559],{"nctId":560,"briefTitle":561,"status":61,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT00493389","Cortisol Response to Adrenocorticotrophin (ACTH) in Acute Stress",[42],"2009-07","2007-07",80,[567],"Aortic Aneurysm, Abdominal",[545],{"intervention":570,"totalTrials":46,"cells":571},"eCBTi-obj",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":573,"activeCount":11},[],{"trials":575,"activeCount":11},[],{"trials":577,"activeCount":11},[],{"trials":579,"activeCount":11},[],{"trials":581,"activeCount":11},[],{"trials":583,"activeCount":11},[584],{"nctId":585,"briefTitle":586,"status":61,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":595},"NCT05990855","Using Sleep Wearables to Adapt Cognitive-behavioral Therapy for Insomnia in the Context of Depression (CBTiA)",[42],"2025-01","2023-08",52,[592,593,594],"Insomnia","Major Depressive Disorder","Persistent Depressive Disorder",[570]]